All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 27, 2023
Home » Authors » John Fox

John Fox

Articles

ARTICLES

Cancer research illustration

New phospholipid anticancer target identified

May 20, 2022
By John Fox
No Comments
A multicenter Japanese study led by researchers at Tokyo University of Science has confirmed that the epithelial phospholipid, phosphatidylinositol bisphosphate, could partially halt cancer progression, making it an attractive new target molecule for novel anticancer treatments.
Read More
Woman wearing eye mask while sleeping

Study reveals dopamine as a sleep disorders target

March 14, 2022
By John Fox
No Comments

The discovery of increased levels of dopamine in the basolateral amygdala of the brain at the transition from non-rapid eye movement (NREM) to REM sleep in mice suggests a druggable sleep disorder target, according to a Japanese study.


Read More
Petri dishes

Study casts new light on autoimmune disease etiology

March 10, 2022
By John Fox
No Comments
Major histocompatibility complex (MHC) class II molecules aberrantly induced by viral infection or inflammation, have been shown for the first time to form self-antigen/MHC class II complexes that initiate autoantibody production, according to a Japanese study published in the March 4, 2022, edition of Science Advances.
Read More
Lymph nodes

Genetic findings pave way to treatment of lymph disorder

March 7, 2022
By John Fox
No Comments
An international collaboration led by scientists at The University of South Australia, SA Pathology in Adelaide, and the de Duve Institute, University of Louvain, Belgium, has discovered biallelic MDFIC pathogenic variants underlying the severe lymphatic disorder, central conducting lymphatic anomaly (CCLA), in seven people from six separate families.
Read More
Neurons

Study finds potential entry points to Huntington's therapy

March 1, 2022
By John Fox
No Comments
A Chinese study led by researchers at Fudan University in Shanghai has described a novel strategy to target the "undruggable" mutant Huntingtin protein by screening for compounds that directly bind to the 'undruggable' target and rescue disease-relevant phenotypes.
Read More
Skeletal system

Study identifies potential new bone disease target

Feb. 28, 2022
By John Fox
No Comments
Scientists at Osaka University have discovered that intercellular communication via extracellular vesicles from osteoblasts, cells that are specialized for laying down new bone, is a key factor for the transition from bone formation to resorption via a microRNA (miRNA)-mediated mechanism.
Read More
Neurology illustration

Engineered Wnt ligands repair BBB in neuro disorders

Feb. 22, 2022
By John Fox
No Comments
An international study led by scientists at the Free University of Brussels in Belgium has shown that Wnt ligand signaling specificity is adjustable and may represent a means of treating CNS disorders by normalizing blood-brain barrier (BBB) function.
Read More
Prostate cancer cells

Advanced prostate cancer antibody successful in dogs

Feb. 10, 2022
By John Fox
No Comments
A Japanese study has shown that targeting the chemokine receptor CCR4 using treatment with the monoclonal antibody mogamulizumab (Poteligeo, Kyowa, Amgen) depleted immune regulatory T cells and significantly improved survival in a canine model of advanced prostate cancer.
Read More
Cross-section of brain

Selenium mediates neurogenesis after hippocampal injury

Feb. 7, 2022
By John Fox
No Comments

An international collaborative study led by Australian scientists at the University of Queensland in Brisbane has demonstrated that dietary selenium supplementation mediates exercise-induced adult neurogenesis and reverses learning deficits induced by hippocampal injury and aging in mice.


Read More
Mycobacterium tuberculosis

Epigenetic-mediated immune mechanisms identified in TB

Feb. 3, 2022
By John Fox
No Comments
A histone acetylome-wide associations study performed in immune cells from patients with active Mycobacterium tuberculosis infection versus those from healthy controls, has for the first time provided proof of principle for HAWAS to infer molecular mechanisms of host response to pathogens.
Read More
View All Articles by John Fox

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 26, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 26, 2023.
  • FDA approved icons and medical professional

    Genmab, Abbvie to join Roche with FDA nod for CD20 bispecific in lymphoma

    BioWorld
    Five months after the first anti-CD20xCD3 T-cell engaging bispecific antibody, Roche Holding AG’s Lunsumio (mosunetuzumab), cleared U.S. FDA approval for...
  • Illustration of pancreas

    Gene therapy to reverse T2D shows proof of concept at ASGCT

    BioWorld
    The most ambitious objective of any treatment is to eradicate the disease, acting on its origin to cure it instead of treating its symptoms. This is the purpose...
  • PET imaging of RELN-COLBOS (H3447R) carrier brain showing limited aggregation of tau

    Reelin’ in druggable protective pathways with second Alzheimer’s ‘escapee’

    BioWorld
    Investigators have identified a second individual who remained cognitively normal into his late 60s despite having the PSEN1 E280A mutation, which causes a...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing